[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemo-brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemo-brain":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,75,98,128,158,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100635499","chemotherapy-induced-hearing-loss-and-health-inequality-100635499",false,"NCT07553481","Chemotherapy-Induced Hearing Loss and Health Inequality","CANHEAR","Inclusion Criteria:\n\n* Patients receiving platinum-based chemotherapy drugs\n* Living and treated within North West England\n* Able to complete an online hearing and cognitive test\n* Fluent in English\n\nExclusion Criteria:\n\n* Following cancer types: brain tumour\u002Fmetastasis, head + neck, skin cancers around the ear, and adenoid cystic carcinoma of the auditory cortex\n* World Health Organisation performance status score of 3 or more\n* Stage 4 cancer\n* History of childhood deafness\n* Current or recent ear infections\n* Cochlear implant user\n* Known neurological impairment (e.g., stroke, traumatic brain injury, dementia)\n* Patients who look capacity to consent or complete study tasks","ALL","18 Years",{"count":19,"type":20},172,"ESTIMATED","OBSERVATIONAL","This project aims to understand how platinum-based chemotherapy affects hearing function in cancer patients from different socioeconomic backgrounds in the North West of England. Platinum-based chemotherapy drugs, such as cisplatin, are ototoxic, meaning that they cause permanent damage to the hair cells of the ear, resulting in hearing loss. Patients from more deprived backgrounds face additional risk factors to their hearing health, including limited healthcare access, greater occupational noise exposure, and poorer overall health, making them more vulnerable to hearing loss.\n\nThis is especially concerning as hearing loss can make communication more challenging, which creates a greater reliance on cognitive processes such as thinking and memory to navigate social interactions. This challenge is exacerbated when individuals experience cognitive dysfunction related to chemotherapy, commonly referred to as 'chemo brain'. Addressing these communication difficulties is crucial for promoting healthy ageing and maintaining social engagement. It is expected that cancer patients from the most deprived backgrounds would experience greater hearing loss following chemotherapy than those from less deprived backgrounds.\n\nAs a secondary aim, this study will also investigate how hearing loss may affect cognitive function. Specifically, it will assess whether differences in speech-in-noise performance from pre- to post-treatment predict cognitive performance post-treatment, to understand if changes in hearing over time are associated with changes in cognition. The study will also explore how socioeconomic deprivation, cumulative chemotherapy dose, and treatment duration influence these relationships. By identifying disparities in hearing loss and possible associations with cognition, this research will help guide future hearing screening and intervention strategies for cancer patients.",[24,25,26,27],"Cancer","Chemo Brain","Chemotherapy","Hearing",[24,29,26,27],"Chemo brain","NOT_YET_RECRUITING","2026-04-20",{"date":33,"type":34},"2026-04-28","ACTUAL",{"date":36,"type":20},"2026-05-02",{"date":38,"type":20},"2028-09-01",{"name":40,"class":41},"Lancaster University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100231453","chemotherapy-induced-cognitive-and-brain-changes-in-older-adults-with-breast-cancer-100231453","NCT02290834","Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer","Inclusion Criteria:\n\n* Breast cancer patients treated with chemotherapy- Group 1 (experimental group)\n\n  * Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +\u002F- imaging components of study\n  * New diagnosis histologically confirmed invasive breast cancer\n  * Treatment plan to include chemotherapy\n  * Female subjects age ≥ 60 years.\n  * Life expectancy ≥ 1 year\n  * Karnofsky Performance Score (KPS) ≥ 80\n  * Ability to understand and the willingness to sign a written informed consent document.\n* Non-treated breast cancer patient controls- Group 2 (control group)\n\n  * Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +\u002F- imaging components of study:\n  * New diagnosis histologically confirmed invasive breast cancer\n  * Treatment plan does not include chemotherapy\n  * Age ≥ 60 years.\n  * Life expectancy ≥ 1 year\n  * Karnofsky Performance Score (KPS) ≥ 80\n  * Ability to understand and the willingness to sign a written informed consent document.\n* Healthy control subjects- Group 3 (control group)\n\n  * Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +\u002F- imaging components of study:\n  * Age ≥ 60 years.\n  * Life expectancy ≥ 1 year\n  * Karnofsky Performance Score (KPS) ≥ 80\n  * Ability to understand and the willingness to sign a written informed consent document.\n  * Participants with well-controlled vascular risk factors, such as treated hypertension, treated hyperlipidemia or well-controlled Type II diabetes (glucose levels \\\u003C250) may be included.\n  * Serum Pregnancy Testing: STAT quantitative serum hCG pregnancy testing for all women of childbearing potential. Imaging will not start until and unless the test result returns negative.\n\nExclusion Criteria:\n\n* Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study:\n\n  * Participants with clinical or radiographic evidence of metastatic CNS disease\n  * Subjects with MMSE scores below 24\n  * Active or history of major psychiatric disorders such as schizophrenia, schizoaffective disorder, major affective disorder in mid-life, or treatment with ECT (Mild depression that is well treated with stable dose of SSRI antidepressants may be allowed).\n  * Substance abuse within the past 2 years\n  * Huntington's disease, hydrocephalus or seizure disorder\n* In addition to exclusion criteria above, participants who exhibit any of the following conditions at screening will not be eligible for admission into imaging portion of the study:\n\n  * Participants with contraindications to MRI (i.e., implanted metal including pacemakers, cerebral spinal fluid shunts, aneurysm clips, artificial heart valves, ear implants or metal\u002Fforeign objects in the eyes and those with a history of claustrophobia), injuries to the eyes with metal without X-ray documentation that metal was removed",true,"FEMALE","60 Years",{"count":53,"type":20},200,"INTERVENTIONAL",[56],"NA","This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.",[59,60,61],"Impaired Cognition","Chemo-brain","Breast Cancer",[63,60],"Chemotherapy related cognitive impairment","RECRUITING","2026-03-09",{"date":67,"type":34},"2026-03-11",{"date":69,"type":4},"2015-03",{"date":71,"type":20},"2028-01",{"name":73,"class":41},"Massachusetts General Hospital",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":54,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":42},"100627887","phase-4-edaravone-and-dexborneol-sublingual-tablet-for-treating-chemotherapy--induced-cognitive-impairment-study-100627887","NCT07454473","Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study","EDS-CICI","Inclusion Criteria:\n\n* 1\\. Patients receiving \\*\\*monotherapy with any chemotherapeutic agent\\*\\* (including but not limited to):\n* \\*Alkylating agents\\*: Cyclophosphamide, Carmustine, Lomustine, Temozolomide, etc.\n* \\*Antimetabolites\\*: 5-Fluorouracil, Methotrexate, Capecitabine, Gemcitabine, etc.\n* \\*Platinum-based drugs\\*: Cisplatin, Carboplatin, Oxaliplatin, etc.\n* \\*Taxanes\\*: Paclitaxel, Docetaxel, etc.\n* \\*Anthracyclines\\*: Doxorubicin, Epirubicin, etc.\n* \\*Other agents\\*: Vincristine, Etoposide, Irinotecan, etc.\n\n  * and\\*\\* meeting all subconditions\\*\\*:\n* No concurrent use of other therapeutic drugs\n* Histologically confirmed malignant tumor (excluding central nervous system tumors) requiring chemotherapy\n* Availability of tissue biopsy results\n\n  2\\. Full comprehension of the study's purpose, potential adverse reactions, and provision of \\*\\*written informed consent\\*\\*.\n\n  3\\. Aged \\*\\*35-80 years\\*\\*, fluent in Chinese, cognitively capable of completing questionnaires independently, \\*\\*with caregiver assistance\\*\\* for questionnaire completion.\n\n  4\\. Initial complaint of cognitive impairment (memory and\u002For other domains) \\*\\*occurring ≥3 months before chemotherapy initiation\\*\\*.\n\n  5\\. Completion of cancer treatment with \\*\\*curative intent\\*\\* (excluding post-chemotherapy endocrine therapy).\n\n  6\\. \\*\\*Clinical Dementia Rating (CDR)\\*\\* global score of \\*\\*0.5-2\\*\\* (indicating questionable to moderate cognitive impairment) and \\*\\*no significant visual or auditory deficits\n\nExclusion Criteria:\n\n* 1\\. Established diagnosis of \\*\\*cognitive impairment disorders\\*\\* (e.g., Alzheimer's disease, frontotemporal dementia, Parkinson's dementia).\n\n  2\\. Primary or metastatic \\*\\*central nervous system malignancies\\*\\*. 3. History of \\*\\*brain metastases or other intracranial tumors\\*\\*. 4. Severe \\*\\*head trauma\\*\\* or stroke with significant residual deficits (\\*\\*Activities of Daily Living \\[ADL\\] score \\\u003C 60\\*\\*).\n\n  5\\. Poorly controlled \\*\\*epilepsy\\*\\* or other seizure disorders. 6. \\*\\*Contraindications to MRI\\*\\* (e.g., claustrophobia, cardiac pacemakers, metal implants) - \\*excluded from fMRI testing only\\*; otherwise eligible participants may enroll without fMRI.\n\n  7\\. Current use of \\*\\*cognition-affecting medications\\*\\*, including but not limited to:\n* \\*Cholinesterase inhibitors\\*: Donepezil, Rivastigmine, Galantamine\n* \\*NMDA receptor antagonists\\*: Memantine\n* \\*Other agents\\*: Sodium oligomannate, Ginkgo biloba extract, Oxiracetam, Piracetam, Nicergoline, Lecanemab, Aducanumab 8. \\*\\*Pregnancy\\*\\*, lactation, or plans for pregnancy. 9. Active \\*\\*neurological or untreated\u002Funremitted psychiatric disorders\\*\\* (e.g., active major depressive disorder per DSM-5; \\*stable treated depression permitted\\*).\n\n  10\\. \\*\\*Alcohol\u002Fsubstance abuse or dependence\\*\\* within the past 2 years. 11. \\*\\*Clinically significant systemic diseases\u002Funstable medical conditions\\*\\*, including:\n* Cardiac: Myocardial infarction (≤1 year), unstable angina, congestive heart failure, or clinically abnormal ECG\n* Pulmonary: Acute asthma exacerbation, pulmonary embolism\n* Gastrointestinal: Active bleeding, inflammatory bowel disease\n* Hepatic: Cirrhosis or ALT\u002FAST \\>2× ULN\n* Renal: Serum creatinine \\>1.5× ULN 12. Use of \\*\\*non-study cognition-enhancing drugs\\*\\* within 4 weeks prior to enrollment.\n\n  13\\. Use of edaravone dexborneol within 30 days prior to enrollment.","35 Years","80 Years",{"count":85,"type":20},80,[87],"PHASE4","Chemotherapy-induced cognitive impairment (CICI), also known as \"chemobrain,\" is a range of neurocognitive deficits experienced during and after cancer chemotherapy. It is also one of the significant factors affecting the quality of life of cancer patients. Due to patients' subjective feelings, the definition of cognitive impairment, the variety of testing scales, and the lack of pre-chemotherapy cognitive function measurements, it is difficult to determine its incidence rate. Consequently, the diagnosis and treatment of this condition are delayed. Existing studies report a high incidence of CICI, affecting 17% to 78% of survivors, and it may persist for years after chemotherapy cessation, leading to more severe progressive manifestations. Its main clinical presentations include deficits in attention, memory, reasoning, multi-tasking ability, decision-making ability, as well as learning and language impairments. These significantly affect patients' functional independence, imposing a heavy burden on families and society. Numerous studies have proposed several potential mechanisms and etiologies for CICI, including direct neurotoxicity of chemotherapeutic drugs, blood-brain barrier disruption, reduced hippocampal neurogenesis, white matter abnormalities, secondary neuroinflammatory responses, and increased oxidative stress. However, the exact underlying mechanisms remain unclear. Currently, there is no clear and effective diagnosis or treatment method for CICI. How to effectively diagnose and treat cognitive impairment caused by chemobrain remains a key focus and challenge in current research.\n\nPrevious studies indicate that in the treatment of ischemic stroke, Edaravone exerts its effects by scavenging oxygen free radicals, reducing inflammatory responses, mitigating neuronal and endothelial cell damage, and inhibiting excitatory neurotoxicity. It also inhibits neuronal lipid peroxidation and alleviates brain tissue damage and cerebral edema caused by cerebral ischemia and hypoxia. Dexborneol, as a bicyclic monoterpenoid compound, can also inhibit inflammatory responses, protect blood-brain barrier permeability, and reduce cell apoptosis. The combination of these two active ingredients can exert multiple mechanisms of action, including free radical scavenging, anti-inflammation, and blood-brain barrier protection, significantly reducing neuronal damage caused by acute ischemic stroke and exerting neuroprotective effects. Clinically, it effectively reduces infarct volume and improves neurological function.\n\nThe aforementioned pathogenesis of CICI precisely involves increased neuroinflammation and oxidative stress, as well as damage to the blood-brain barrier. Furthermore, the sublingual tablet dosage form offers advantages in convenience compared to injections. Based on this, we hypothesize that Edaravone Borneol sublingual tablets may also have considerable efficacy in treating chemotherapy-related cognitive impairment.\n\nThis study addresses a clinical cross-disciplinary event in neurology and oncology. It aims to evaluate the efficacy of Edaravone Dexborneol sublingual tablets for CICI and conduct preliminary exploration of early diagnostic biomarkers for CICI by collecting clinical patient imaging data, blood samples, and neuropsychological scale results. This will ultimately help optimize chemotherapy regimens to the greatest extent.",[25],"2026-03-02",{"date":92,"type":34},"2026-03-06",{"date":90,"type":20},{"date":95,"type":20},"2027-12-31",{"name":97,"class":41},"Chuansheng Zhao",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":49,"sex":50,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":54,"phases":108,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":42},"100505660","improve-cancer-related-cognitive-impairment-100505660","NCT05864274","Improve Cancer-related Cognitive Impairment","Using a Novel Mobile Cognitive Training Application to Improve Cancer-related Cognitive Impairment in Gynecologic Oncology Patients","Inclusion criteria are:\n\n* newly diagnosed gynecologic malignancy (uterine, cervical, ovarian, primary peritoneal, vulvar, or vaginal) and undergoing chemotherapy\n* own a smartphone or tablet with ability to download cognitive training application\n* and age \\>21 years old\n\nExclusion criteria include:\n\n* medical diagnosis of dementia\n* significant underlying mental diagnoses for which they are on more than 1 medication for (patients with depression or anxiety on single-agent therapy will be able to participate\n* age \\\u003C21","90 Years",{"count":107,"type":20},64,[56],"Cancer-related cognitive impairment (CRCI), also known as \"chemobrain,\" is the cognitive decline that negatively impacts the majority of cancer patients undergoing chemotherapy, radiation, and\u002For hormonal treatments. This application focuses on evaluating if using a cognitive mobile training application can decrease the impact of CRCI in gynecologic oncology patients through a multidisciplinary approach with patients undergoing assessments by our neurocognitive team.",[111,112,60,113],"Gynecologic Cancer","Chemotherapy Effect","Cancer-related Cognitive Difficulties",[115,116,117,118],"CHEMOTHERAPY SIDE EFFECTS","GYNECOLOGIC CANCERS","CHEMO-BRAIN","CANCER-RELATED COGNITIVE IMPAIRMENT","2025-11-18",{"date":121,"type":34},"2025-11-24",{"date":123,"type":34},"2024-09-01",{"date":125,"type":20},"2027-08-01",{"name":127,"class":41},"University of Alabama at Birmingham",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":25,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":136,"conditions":137,"keywords":144,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":42},"100440369","cognitive-impairment-in-colorectal-cancer-patients-receiving-cytotoxic-chemotherapy-100440369","NCT05014399","Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy","Inclusion Criteria:\n\n* Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry.\n* A histologically-confirmed colorectal tumor\n* Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.\n* Patients must not have received cytotoxic chemotherapy previous to enrollment.\n\nExclusion Criteria:\n\n* Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n* Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys\n* Pregnant or breastfeeding\n* Any known brain metastases\n* Non-English speaking patients\n* Patients who have been diagnosed with any neuro-cognitive disorder including traumatic brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Creutzfeldt-Jakob disease.\n* Patients deemed inappropriate to participate in this study by the study PI or coordinator will be excluded.",{"count":135,"type":20},60,"The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.",[138,139,140,141,60,142,112,143],"Neoplasm, Colorectal","Cognitive Impairment","Cognitive Dysfunction","Cognitive Change","Chemo Fog","Cognitive Decline",[145,146,147,148,139,25],"Palliative Care","Palliative Oncology","Supportive Care","Supportive Oncology","2025-06-06",{"date":151,"type":34},"2025-06-11",{"date":153,"type":34},"2021-09-20",{"date":155,"type":20},"2031-10",{"name":157,"class":41},"Joseph McCollom",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":49,"sex":16,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":170,"conditions":171,"keywords":180,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":42},"100503846","investigating-cognitive-impairment-in-young-patients-with-cancer-prospectively-100503846","NCT05840575","Investigating Cognitive Impairment in Young Patients With Cancer Prospectively","A Multidisciplinary Neuroscience Approach to Investigate Cognitive Impairment in Young Patients With Cancer Prospectively","MyBrain","Inclusion Criteria:\n\n* Patients who are newly diagnosed with a non-CNS cancer and will undergo chemotherapy at University Hospital Copenhagen, Rigshospitalet.\n* At the age of 7-29 years at diagnosis\n* Each patient is matched (1:1) with a control participant within 24 months of age. The controls are recruited from the patient's own social circle and can be a friend, partner, or close family (sibling or cousin).\n\nExclusion Criteria:\n\n* Unable to speak and understand Danish\n* Severe intellectual disability or mental health disorder that hinders participation\n* Brain metastases,\n* Terminal illness\n* Have had a previous chemotherapy or radiotherapy treatment","7 Years","29 Years",{"count":169,"type":20},100,"The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function.\n\nThe aim of the study is to better understand the trajectories of cognitive functioning and measures that have been associated with cognitive impairment in patients treated with chemotherapy.",[172,173,60,24,174,175,176,177,178,179],"Chemotherapy-Related Cognitive Impairment","Chemotherapeutic Toxicity","Childhood Cancer","Hodgkin Lymphoma","Non Hodgkin Lymphoma","Testicular Cancer","Sarcoma","Leukemia",[181,182,183,184],"Cognition","Neuropsychology","Electroencephalogram","Biomarkers","2023-04-24",{"date":187,"type":34},"2023-05-03",{"date":189,"type":34},"2022-03-01",{"date":191,"type":20},"2027-03-01",{"name":193,"class":41},"Rigshospitalet, Denmark",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":49,"sex":50,"minAge":4,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":42},"100462701","assessment-of-brain-cognitive-impairment-in-breast-cancer-100462701","NCT05305092","Assessment of Brain Cognitive Impairment in Breast Cancer","Integrated PET\u002FMRI Study of Cognitive Impairment in Premenopausal Breast Cancer Patients After Chemotherapy or Endocrine Therapy","Inclusion Criteria:\n\n* Patients with primary stage I-II breast cancer.\n* Premenopausal women (menopausal status determined by National Comprehensive Cancer Network Breast Cancer Guidelines criteria).\n* No treatment other than surgery has been started (if neoadjuvant chemotherapy is required before surgery, enroll before chemotherapy starts).\n* Eastern Cooperative Oncology Group score of 0-1 points.\n* Can understand and complete various scales.\n* Right handedness.\n* Female subjects of childbearing potential must be willing to use a medically-approved high-efficiency contraceptive method (eg, intra-uterine device, birth control pill, or condom) for the duration of the study.\n* Sign the informed consent and voluntarily participate in this clinical observation.\n\nExclusion Criteria:\n\n* Central nervous system (CNS) disease, history of malignancy, chronic loss of consciousness, head trauma, and any disease affecting cognitive function.\n* Current or former epilepsy, dementia, or learning disabilities.\n* Past psychiatric history.\n* Past history of malignancy.\n* MRI related contraindications: pacemakers, defibrillators, hearing aids, insulin pumps, drug dose control devices and other metal implants; patients with severe hyperthermia; patients with claustrophobia.",{"count":202,"type":20},90,"To explore the cognitive impairment caused by chemotherapy and endocrine therapy in premenopausal breast cancer patients and to find biomarkers with early predictive effect on this cognitive impairment by using multimodal integrated PET\u002FMRI technology combined with psychobehavioral technology.",[61,60,205],"Endocrine Therapy",[207,208,209,184],"CRCI","psycho-behavioral technology","Integrated PET\u002FMRI technology","2022-07-12",{"date":212,"type":34},"2022-07-13",{"date":214,"type":34},"2022-05-31",{"date":216,"type":20},"2027-05-30",{"name":218,"class":41},"Tang-Du Hospital"]